AstraZeneca accepted in a legal submission that their Covid vaccine Covishield can cause Thrombosis with Thrombocytopenia Syndrome. | Latest News India
AstraZeneca reaffirms commitment to patient safety and safety profile of vaccines amid concerns over rare side effects of COVID-19 vaccine. AstraZeneca had acknowledged that its Covid vaccines, Covishield and Vaxzevria, ‘can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)’.
The admission came a day after the pharma giant admitted in a UK court that its COVID-19 vaccine sold globally as Covishield and Vaxzevria may cause Thrombocytopenia Syndrome (TTS) in "very rare cases".
AstraZeneca, following global outrage over the side effects of the vaccine, said on Tuesday that the benefits of the vaccine “far outweigh” the risks of “extremely rare” potential side effects. - Benefits Of Covishield COVID Vaccine Far Outweigh Extremely Rare Potential Side Effects: AstraZeneca
It has been known for quite some time now that the viral vector-based Wuhan coronavirus (Covid-19) "vaccine" from drug giant AstraZeneca, known as Vaxzevria, causes a "rare" [.]